Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SNOA
SNOA logo

SNOA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.590
Open
2.560
VWAP
2.43
Vol
18.07K
Mkt Cap
4.12M
Low
2.330
Amount
43.97K
EV/EBITDA(TTM)
--
Total Shares
1.73M
EV
1.96M
EV/OCF(TTM)
--
P/S(TTM)
0.24
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Show More

Events Timeline

(ET)
2025-11-13
08:49:28
Sonoma Pharmaceuticals' Reliefacyn Advanced Earns NRS Seal of Acceptance
select
2025-11-04 (ET)
2025-11-04
08:57:47
Sonoma Pharmaceuticals announces Q2 earnings per share of 32 cents, compared to a loss of 59 cents in the same period last year.
select
2025-10-14 (ET)
2025-10-14
08:39:33
Sonoma Pharmaceuticals and Medline Introduce HOCI Wound Cleansing Solution
select
2025-10-07 (ET)
2025-10-07
09:26:00
Sonoma Pharmaceuticals Registers Facial Spray with FDA's MoCRA
select
2025-04-22 (ET)
2025-04-22
16:15:05
Sonoma Pharmaceuticals registers acne products in the United Kingdom
select
2024-11-21 (ET)
2024-11-21
15:16:37
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines
select
2024-10-22 (ET)
2024-10-22
08:43:52
Sonoma Pharmaceuticals expands partnership with healthcare distributor
select
2024-09-19 (ET)
2024-09-19
08:44:53
Sonoma Pharmaceuticals regains compliance with Nasdaq requirement
select
2024-09-11 (ET)
2024-09-11
08:44:55
Sonoma Pharmaceuticals, EMC Pharma enter co-marketing collaboration
select
2024-07-15 (ET)
2024-07-15
03:35:02
Sonoma Pharmaceuticals enters distribution agreement for wound care products
select

News

seekingalpha
9.5
02-10seekingalpha
Sonoma Pharmaceuticals Reports Q3 Earnings
  • Earnings Report: Sonoma Pharmaceuticals reported a Q3 GAAP EPS of -$0.48, indicating challenges in profitability that could affect investor confidence.
  • Revenue Performance: The company generated $4.3 million in revenue, which, while showing some sales, may fall short of market expectations, reflecting volatility in product demand.
  • Market Reaction: Ongoing losses and revenue underperformance may lead investors to adopt a cautious stance on Sonoma's future growth prospects, putting pressure on the stock price.
  • Strategic Adjustments: The company may need to reassess its market strategies and product lines to address current financial challenges and seek pathways to improve profitability.
Benzinga
2.0
2025-08-21Benzinga
5 Healthcare Stocks Soaring This Week
  • Top Performing Healthcare Stocks: Five healthcare stocks, including Sonoma Pharmaceuticals, Evoke Pharma, KALA Bio, Ginkgo Bioworks, and Soligenix, have shown significant week-on-week momentum gains, indicating potential breakout opportunities in the sector.

  • Sonoma Pharmaceuticals Highlights: Leading the pack, Sonoma Pharmaceuticals experienced a remarkable 66.73-point momentum score increase, driven by its focus on antimicrobial and dermatology products, with a 44.60% surge over the last month.

  • Evoke Pharma and KALA Bio Performance: Evoke Pharma's momentum score rose significantly due to its gastrointestinal treatment product, while KALA Bio saw a strong increase linked to therapies for rare ocular diseases, both showing impressive price trends.

  • Market Context and Momentum Ranking: The Benzinga Edge Rankings report highlights that these stocks' dramatic momentum gains reflect strong price performance and volatility, despite broader market declines in major ETFs like SPY and QQQ.

NASDAQ.COM
2.0
2025-08-15NASDAQ.COM
Stocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers
  • Premarket Trading Activity: Notable premarket trading activity is observed, indicating potential opportunities for traders to identify breakouts or reversals before the market opens.

  • Stock Movements: Several stocks are showing significant percentage increases while others are experiencing notable declines in Friday's premarket session.

TipRanks
4.5
2025-08-14TipRanks
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
  • Stock Market News: Investors are encouraged to check TipRanks for the latest headlines and significant stories in the stock market on Thursday.

  • Resource Availability: TipRanks offers a comprehensive collection of major stock market stories worth reading today.

Benzinga
4.5
2025-08-14Benzinga
Dow Falls Over 100 Points; Deere Shares Dip After Q3 Results
  • U.S. Stock Market Performance: U.S. stocks mostly declined, with the Dow Jones dropping over 100 points and sectors like materials falling by 1.4%, while communication services saw a slight increase of 0.2%. Notable stock movements included Deere & Company shares falling 6% after lowering its income outlook, while Expion360 Inc surged 203% following strong quarterly results.

  • Global Market Trends: European shares were generally higher, with Spain's IBEX 35 rising 0.9%, while Asian markets closed mixed, with Japan's Nikkei 225 down 1.45%. Additionally, U.S. initial jobless claims decreased to 224,000, and producer prices rose by 0.9% month-over-month in July.

TipRanks
5.0
2025-08-14TipRanks
Why Is Sonoma Pharmaceuticals Stock (SNOA) Up 105% Today?
  • Stock Performance: Sonoma Pharmaceuticals (SNOA) stock surged 103.8% in pre-market trading after launching its hypochlorous acid-based diaper cream at major U.S. retailers, including Walmart and Amazon, despite a 35.04% decline over the past year.

  • Analyst Rating: TipRanks AI analyst Spark rates SNOA stock as Neutral with a $3 price target, citing concerns over poor financial performance marked by declining revenues and negative cash flows.

Valuation Metrics

The current forward P/E ratio for Sonoma Pharmaceuticals Inc (SNOA.O) is -3.91, compared to its 5-year average forward P/E of -1.16. For a more detailed relative valuation and DCF analysis to assess Sonoma Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.16
Current PE
-3.91
Overvalued PE
0.18
Undervalued PE
-2.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.77
Undervalued EV/EBITDA
-0.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.26
Current PS
0.29
Overvalued PS
0.36
Undervalued PS
0.16

Financials

AI Analysis
Annual
Quarterly

Whales Holding SNOA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Sonoma Pharmaceuticals Inc (SNOA) stock price today?

The current price of SNOA is 2.38 USD — it has decreased -8.81

What is Sonoma Pharmaceuticals Inc (SNOA)'s business?

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

What is the price predicton of SNOA Stock?

Wall Street analysts forecast SNOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNOA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sonoma Pharmaceuticals Inc (SNOA)'s revenue for the last quarter?

Sonoma Pharmaceuticals Inc revenue for the last quarter amounts to 4.35M USD, increased 22.03

What is Sonoma Pharmaceuticals Inc (SNOA)'s earnings per share (EPS) for the last quarter?

Sonoma Pharmaceuticals Inc. EPS for the last quarter amounts to -0.48 USD, decreased -23.81

How many employees does Sonoma Pharmaceuticals Inc (SNOA). have?

Sonoma Pharmaceuticals Inc (SNOA) has 168 emplpoyees as of March 12 2026.

What is Sonoma Pharmaceuticals Inc (SNOA) market cap?

Today SNOA has the market capitalization of 4.12M USD.